Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia. - Test2 - elhamkhani - TriplyDB

Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia.

Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia.

http://www.wikidata.org/entity/Q38087390

about

Maytansine-loaded star-shaped folate-core PLA-TPGS nanoparticles enhancing anticancer activity Spontaneous Isopeptide Bond Formation as a Powerful Tool for Engineering Site-Specific Antibody-Drug Conjugates.Linker stability influences the anti-tumor activity of acetazolamide-drug conjugates for the therapy of renal cell carcinoma.Immunotoxins for leukemia.Emerging drugs for acute lymphocytic leukemia.Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas.Novel reduction-sensitive micellar nanoparticles assembled from Rituximab-doxorubicin conjugates as smart and intuitive drug delivery systems for the treatment of non-Hodgkin's lymphoma.Antibody Drug Conjugates (ADCs): Changing the Treatment Landscape of Lymphoma.Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody-Drug Conjugates.Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.

P2860

Q28654242-2C27EE16-C10B-4DD9-BC10-AC5893875665 Q30396530-63EEB478-7422-4FA8-907B-FBA79B7BDA9D Q37606966-F8D13813-34A9-41BA-A675-FEAB84BC52DA Q37709336-9298C1C9-6BDE-4953-BF84-E7104D25D8A0 Q38172586-97531253-225F-481A-BBAA-3D315B0D191B Q38379829-D730C95B-F6BE-458B-982C-4B7186282D01 Q38706179-F4846E67-C46A-4C69-BEBA-8B3754F12A33 Q38932868-33C80407-884E-4F7C-A22D-829AD4029CBA Q48199774-F7A1868A-413A-42F4-9600-CF3E19C8686D Q53033031-1158F87B-4789-4794-AC8B-5945B5868C19

P2860

Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia.

http://www.wikidata.org/entity/Q38087390

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia.

@en

type

label

Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia.

@en

prefLabel

Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia.

@en

P1433

Q38087390-7B021643-E9D5-4522-A5BD-891A534C2246

P1476

Q38087390-393DA468-F27E-46E2-8093-AF649EAFCE8A

P2093

Q38087390-25B8AEDD-D595-42E4-BB5E-7ECB1407AD12

Q38087390-E55FCFD4-7588-43B8-81BF-3557F36C99BC

P2860

Q38087390-0105FE49-2FDF-40CE-8D99-303C92A89A43

Q38087390-0B917314-12EE-46DC-BEB4-62FDB04F9788

Q38087390-0F435B53-3C74-4261-B6B5-3962433E410A

Q38087390-138AB212-D84E-425C-A059-A6CB089A19BD

Q38087390-1F4505D4-BDE0-4335-976E-EDBFA57035A3

Q38087390-24D5E84F-44AE-4222-A2BD-EE844F20A425

Q38087390-27DC6AEA-4CAA-449F-8F75-D19FEE15F69C

Q38087390-2FAE6F95-F295-441A-BA43-2B4B4F8F1BDE

Q38087390-347A9AD2-A2B1-4AFB-ACB2-CC49A5FAC134

Q38087390-3C231124-14AC-4822-BB8A-92142EEF1FC4

P304

Q38087390-B518C0DD-CC65-404D-9C18-8AA37DC340F8

P31

Q38087390-CB8E3F99-11D8-43A6-B3D7-2AAF1A49C5EB

P356

Q38087390-6C33C641-FAB4-4617-8A5A-7BAAE494F89E

P407

Q38087390-BD9AFB72-9AE4-481C-83CF-E5E7A0E1AE4B

P433

Q38087390-4C3B1875-DD19-4FEC-A52A-80D8C8BF214C

P478

Q38087390-19FB2649-707E-428D-97F7-F13A1156C7D8

P577

Q38087390-6C50C00E-1C5C-44C5-8FC5-20BE274E81BE

P698

Q38087390-4A02167F-FA4F-45C5-B744-EBA2AEB05864

P356

P1433

Future Oncology

P1476

Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia.

@en

P2093

Andrew Polson

http://www.w3.org/2001/XMLSchema#string

Yu-Waye Chu

http://www.w3.org/2001/XMLSchema#string

P2860

Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Cancer statistics, 2009

Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.

Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy.

Aberrant expression and reverse signalling of CD70 on malignant B cells.

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.

ITAMs versus ITIMs: striking a balance during cell regulation.

P304

355-368

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.12.189

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23469971

http://www.w3.org/2001/XMLSchema#string